Atreca
Atreca
BCEL
OTC
0.09
USD
0.00%
About
Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform.
ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor.
It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 49.9K |
| Three Month Average Volume | 5.5M |
| High Low | |
| Fifty-Two Week High | 1.2 USD |
| Fifty-Two Week Low | 0.052 USD |
| Fifty-Two Week High Date | 16 Jun 2023 |
| Fifty-Two Week Low Date | 19 Mar 2024 |
| Price and Volume | |
| Current Price | 0.09 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -4.49% |
| Thirteen Week Relative Price Change | -50.12% |
| Twenty-Six Week Relative Price Change | -71.04% |
| Fifty-Two Week Relative Price Change | -93.79% |
| Year-to-Date Relative Price Change | -40.13% |
| Price Change | |
| One Day Price Change | -1.32% |
| Thirteen Week Price Change | -47.06% |
| Twenty-Six Week Price Change | -66.67% |
| Five Day Price Change | 0.00% |
| Fifty-Two Week Price Change | -92.37% |
| Year-to-Date Price Change | -31.82% |
| Month-to-Date Price Change | -2.26% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.00694 USD |
| Book Value Per Share (Most Recent Quarter) | 0.27153 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.00694 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.27153 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.87554 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.51742 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.49395 USD |
| Normalized (Last Fiscal Year) | -2.50578 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.51742 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.49395 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.51742 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.49395 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.80445 USD |
| Cash Per Share (Most Recent Quarter) | 0.53977 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.37491 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.3703 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.66931 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 10.39% |
| Tangible Book Value (5 Year) | 19.04% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -8.46% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -54.53% |
| EPS Change (Trailing Twelve Months) | 9.64% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 0 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -21,388,000 |
| Net Debt (Last Fiscal Year) | -70,495,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -81,606,000 |
| Free Cash Flow (Trailing Twelve Months) | -65,385,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -54.72% |
| Return on Assets (Trailing Twelve Months) | -98.54% |
| Return on Assets (5 Year) | -44.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -83.28% |
| Return on Equity (Trailing Twelve Months) | -182.70% |
| Return on Equity (5 Year) | -79.36% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -60.37% |
| Return on Investment (Trailing Twelve Months) | -116.19% |
| Return on Investment (5 Year) | -48.05% |